EMPA-REG OUTCOME Trial What does it mean?
Abstract
Therapeutics Letter 107 explores the findings of the EMP-REG trial. Conclusions: The EMPA-REG OUTCOME Trial tested the addition of empagliflozin to a ‘standard of care’ for T2DM whose impact on clinically important outcomes is currently unknown. It is uncertain whether the reduction in mortality and serious adverse events in the EMPA-REG OUTCOME Trial is attributable to empagliflozin or to less use of other glucose-lowering therapies. The results of this trial are not applicable to people with T2DM in other clinical settings. Until there is a body of evidence informed by large, independently conducted comparative effectiveness trials of different therapeutic strategies, we will not know the optimal treatment of T2DM at various stages of the diagnosis.
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.